Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Etoricoxib for arthritis and pain management

Authors Peter Brooks, Paul Kubler

Published 15 March 2006 Volume 2006:2(1) Pages 45—57

Peter Brooks1, Paul Kubler2


1Executive Dean (Health Sciences), Edith Cavell Building, Royal Brisbane Hospital, Queensland, Australia; 2Staff Specialist Clinical Pharmacology/Rheumatology, Royal Brisbane Hospital & Royal Women’s Hospital and Health Service Districts, Brisbane, Queensland, Australia


Abstract: Nonsteroidal antiinflammatory drugs (NSAIDs), including selective

cyclooxygenase (COX)-2 inhibitors, have come to play an important role in the pharmacologic management of arthritis and pain. Clinical trials have established the efficacy of etoricoxib in osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, low back pain, acute postoperative pain, and primary dysmenorrhea. Comparative studies indicate at least similar efficacy with etoricoxib versus traditional NSAIDs. Etoricoxib was generally well tolerated in these studies with no new safety findings during long-term administration. The gastrointestinal, renovascular, and cardiovascular tolerability profiles of etoricoxib have been evaluated in large patient datasets, and further insight into the cardiovascular tolerability of etoricoxib and diclofenac will be gained from a large ongoing cardiovascular outcomes program (MEDAL). The available data suggest that etoricoxib is an efficacious alternative in the management of arthritis and pain, with the potential advantages of convenient once-daily administration and superior gastrointestinal tolerability compared with traditional NSAIDs. 


Keywords: etoricoxib, cyclooxygenase-2, nonsteroidal antiinflammatory drugs, arthritis, pain

Download Article [PDF] 

Readers of this article also read:

Experimental study of sutureless vascular anastomosis with use of glued prosthesis in rabbits

Vokrri L, Qavdarbasha A, Rudari H, Ahmetaj H, Manxhuka-Kërliu S, Hyseni N, Porcu P, Cinquin P, Sessa C

Vascular Health and Risk Management 2015, 11:211-217

Published Date: 27 March 2015

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair

Liu H, Yang W, Gao H, Jiang T, Gu B, Dong Q, Xu W, Wu S, Sun X

OncoTargets and Therapy 2015, 8:509-518

Published Date: 25 February 2015

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 6 June 2008

Magnetic nanoparticles for gene and drug delivery

Stuart C McBain, Humphrey HP Yiu, Jon Dobson

International Journal of Nanomedicine 2008, 3:169-180

Published Date: 6 June 2008

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Jason W Bennett, James S Lewis II, Michael W Ellis

Therapeutics and Clinical Risk Management 2008, 4:31-40

Published Date: 8 February 2008

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008